

September 13, 2018

BSE Limited
1st Floor, P J Towers,
Dalal Street,
Mumbai-400001

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (East),
Mumbai-400051

Re.: Press Release.

Dear Sir / Madam,

We enclose herewith a copy of press release dated September 13, 2018 titled "Zydus receives final approval from the USFDA for Risedronate Sodium Delayed-Release Tablets".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking You,

Yours faithfully,
For, **CADILA HEALTHCARE LIMITED**


UPEN H. SHAH
COMPANY SECRETARY



Encl.: As above

Zydus receives final approval from the USFDA for Risedronate Sodium Delayed-Release Tablets

Ahmedabad, 13 September, 2018

Zydus Cadila has received the final approval from the USFDA to market Risedronate Sodium Delayed-Release Tablets (US RLD – ATELVIA® delayed-release tablets), 35 mg. It will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.

Risedronate is a medicine of bisphosphonate group that alters bone formation and breakdown in the body. This can slow bone loss and may help prevent bone fractures. This medicine is used to treat osteoporosis in women, caused by menopause.

The group now has 218 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila`

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.
